一家生物制药企业陷入法律争议漩涡。最新提交的司法文件显示，有原告方针对CLIMB BIO INC提起诉讼，要求法院作出宣告式判决，确认该公司旗下实验性药物Budoprutug不符合《美国药品价格竞争与专利期补偿法案》（APA）中关于"产品"的法定定义。
这场法律博弈的核心在于对APA条款的司法解释。原告方主张，Budoprutug作为尚处于研发阶段的候选药物，其法律属性不应被归类为APA监管框架下的"产品"。若法院支持这一主张，或将影响该药物未来面临专利链接制度约束的时点。
目前案件仍在司法程序中，最终裁决结果可能为生物技术行业带来新的判例参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.